Efficacy of EGFR-targeted therapy in anaplastic thyroid cancer
Author Information
Author(s): Nobuhara Y, Onoda N, Yamashita Y, Yamasaki M, Ogisawa K, Takashima T, Ishikawa T, Hirakawa K
Primary Institution: Osaka City University Graduate School of Medicine
Hypothesis
This study investigates the expression of EGFR in anaplastic thyroid cancer cell lines and explores the potential of therapies targeting EGFR as a new therapeutic approach.
Conclusion
EGFR-targeted therapy, such as gefitinib, may be a promising treatment for anaplastic thyroid cancer.
Supporting Evidence
- EGFR was universally expressed in anaplastic thyroid cancer cell lines.
- Gefitinib inhibited the growth of cancer cells that overexpressed EGFR.
- EGFR-targeted therapy showed potential for treating anaplastic thyroid cancer.
Takeaway
This study found that a medicine called gefitinib can help stop the growth of a very aggressive type of thyroid cancer by blocking a special protein that helps the cancer grow.
Methodology
The study used five human anaplastic thyroid cancer cell lines and tested the effects of gefitinib on cell growth and signaling pathways.
Limitations
The study could not show significant effects of gefitinib in normal culture conditions with fetal bovine serum.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website